Angiodynamics vs Procept Biorobotics
Angiodynamics and Procept Biorobotics are similar in size: $320m and $308m of revenue in their latest fiscal years. Procept Biorobotics grew faster (37.2% against 9.5%). Angiodynamics kept more of each dollar of sales as profit: a net margin of -11.5% against -31.0%. Angiodynamics carries less debt relative to equity (0.0% against 14.2%).
| Latest fiscal year | AngiodynamicsANGO, 2026 | Procept BioroboticsPRCT, 2025 |
|---|---|---|
| Revenue | $320m | $308m |
| Revenue growth | 9.5% | 37.2% |
| Net income | −$36.7m | −$95.6m |
| Operating margin | -12.5% | -33.7% |
| Net margin | -11.5% | -31.0% |
| Return on equity | -20.8% | -24.9% |
| Free cash flow | $508,000 | −$58.3m |
| Cash | $53.9m | $287m |
| Total debt | $0 | $52.0m |
| Debt to equity | 0.0% | 14.2% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 632 | 888 |
| Market value | $499m | $1.11bn |
| Price vs our value range | — | — |
| Moat score | 53 (Moderate) | 25 (Weak) |
| Insider trades, 12 months | 0 buys, 3 sales | 8 buys, 14 sales |